Dxd(Exatecan derivative for ADC) CAS:1599440-33-1 is a powerful Exatecan derivative specifically designed for antibody-drug conjugates (ADCs). As a potent DNA topoisomerase I inhibitor, it exhibits an impressive IC50 value of 0.31 μM, showcasing its exceptional cytotoxic capabilities. Utilized as a conjugated drug in the innovative HER2-targeting ADC (DS-8201a), Dxd has emerged as a promising therapeutic agent in the realm of targeted cancer treatment. Its remarkable potency and precise targeting capabilities contribute to the development of safer and more effective cancer therapeutics, paving the way for improved patient outcomes.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.